Latest News and Press Releases

Collaboration establishes an integrated platform for precision medicine clinical trials, combining Oncocyte’s proprietary molecular tests and fully certified pharma services lab with GRN’s nationwide...

IRVINE, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...

IRVINE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...

Event to feature Dr. Naoto Ueno, study investigator and medical oncologist at the University of Texas MD Anderson Cancer Center DetermaIO™, a novel and proprietary test, has been found to...

 Secured National Medicare Reimbursement for DetermaRx™ Starting August 2020 with Final Medicare LCD from Palmetto GBA and Noridian Healthcare Solutions International Distribution...

DetermaRx™ adopted by several community health systems, where most early stage cancer is treated, within first six months of launch Early sites alone represent a potential opportunity of more than...

Event to feature renowned lung cancer experts Dr. David Gandara and Dr. Johannes Kratz DetermaRx™ the first and only predictive test for early stage lung cancer continues to see commercial success...

IRVINE, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...

Noridian's decision aligns with Palmetto GBA's final LCD for the test announced in April Compelling clinical evidence on DetermaRx™ drives the establishment of a new class of predictive tests for...

IRVINE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...